Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 145
Filtrar
1.
Front Endocrinol (Lausanne) ; 13: 943459, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35909553

RESUMEN

TSH receptor (TSHR) antibodies are the cause of Graves' disease and may also be found in patients with Hashimoto's thyroiditis. They come in at least three varieties: thyroid stimulating, thyroid blocking and neutral. The measurement of TSH receptor antibodies in Graves' disease and Hashimoto's thyroiditis is a common clinical activity and can be useful in diagnosis and prognosis. We show that it is not possible to detect the blocking variety of TSHR antibody in patients with Graves' disease because the stimulating antibody may overwhelm the measurement of blocking in the bioassays available for their measurement and may blind the valid interpretation of the results. To help explain this in more detail we show a series of studies with monoclonal TSHR antibodies which support this conclusion.


Asunto(s)
Anticuerpos Monoclonales , Enfermedad de Graves , Enfermedad de Hashimoto , Receptores de Tirotropina , Anticuerpos Monoclonales/análisis , Autoanticuerpos/análisis , Enfermedad de Graves/diagnóstico , Enfermedad de Hashimoto/diagnóstico , Humanos , Receptores de Tirotropina/análisis
2.
J Endocrinol Invest ; 45(4): 773-786, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-34780050

RESUMEN

PURPOSE: To date, many genes have been associated with congenital hypothyroidism (CH). Our aim was to identify the mutational spectrum of 23 causative genes in Turkish patients with permanent CH, including thyroid dysgenesis (TD) and dyshormonogenesis (TDH) cases. METHODS: A total of 134 patients with permanent CH (130 primary, 4 central) were included. To identify the genetic etiology, we screened 23 candidate genes associated with CH by next-generation sequencing. For confirmation and to detect the status of the specific familial variant in relatives, Sanger sequencing was also performed. RESULTS: Possible pathogenic variants were found in 5.2% of patients with TD and in 64.0% of the patients with normal-sized thyroid or goiter. In all patients, variants were most frequently found in TSHR, followed by TPO and TG. The same homozygous TSHB variant (c.162 + 5G > A) was identified in four patients with central CH. In addition, we detected novel variants in the TSHR, TG, SLC26A7, FOXE1, and DUOX2. CONCLUSION: Genetic causes were determined in the majority of CH patients with TDH, however, despite advances in genetics, we were unable to identify the genetic etiology of most CH patients with TD, suggesting the effect of unknown genes or environmental factors. The previous studies and our findings suggest that TSHR and TPO mutations is the main genetic defect of CH in the Turkish population.


Asunto(s)
Hipotiroidismo Congénito/genética , Variación Genética/genética , Antiportadores/análisis , Antiportadores/sangre , Antiportadores/genética , Niño , Preescolar , Oxidasas Duales/análisis , Oxidasas Duales/sangre , Oxidasas Duales/genética , Femenino , Factores de Transcripción Forkhead/análisis , Factores de Transcripción Forkhead/sangre , Factores de Transcripción Forkhead/genética , Secuenciación de Nucleótidos de Alto Rendimiento/métodos , Secuenciación de Nucleótidos de Alto Rendimiento/estadística & datos numéricos , Humanos , Lactante , Recién Nacido , Masculino , Receptores de Tirotropina/análisis , Receptores de Tirotropina/sangre , Receptores de Tirotropina/genética , Transportadores de Sulfato/análisis , Transportadores de Sulfato/sangre , Transportadores de Sulfato/genética , Tiroglobulina/análisis , Tiroglobulina/sangre , Tiroglobulina/genética
3.
Nat Rev Dis Primers ; 6(1): 56, 2020 07 09.
Artículo en Inglés | MEDLINE | ID: mdl-32647173

RESUMEN

Autoimmune gastritis (AIG) is an increasingly prevalent, organ-specific, immune-mediated disorder characterized by the destruction of gastric parietal cells, leading to the loss of intrinsic factor and reduced acid output. These alterations result in malabsorption of iron, vitamin B12 (pernicious anaemia) and potentially other micronutrients. For several years, most studies have focused on pernicious anaemia only, generating confusion between the two entities. In AIG, the gastric proton pump, H+/K+ ATPase, is the major autoantigen recognized by autoreactive T cells. The T cell-dependent activation of B cells stimulates the production of anti-parietal cell antibodies, the serological hallmark of AIG. The role of Helicobacter pylori infection in activating or favouring the autoimmune process is still uncertain. Early histopathological alterations allowing a more precise and prompt recognition have recently been described. AIG is burdened by a substantial diagnostic delay as it can present with varied clinical signs including, among others, gastrointestinal symptoms and neuropsychiatric manifestations. In advanced stages, AIG might progress to neuroendocrine tumours and gastric adenocarcinoma. Management includes early detection through a proactive case-finding strategy, micronutrient supplementation and endoscopic surveillance. This Primer comprehensively describes the most important insights regarding the epidemiology, pathophysiology, diagnosis and management of AIG, focusing on the most controversial, outstanding issues and future directions.


Asunto(s)
Enfermedad de Graves/diagnóstico , Enfermedad de Graves/terapia , Manejo de la Enfermedad , Enfermedad de Graves/fisiopatología , Humanos , Receptores de Tirotropina/análisis , Receptores de Tirotropina/metabolismo
5.
Nucl Med Commun ; 41(3): 212-218, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-31895759

RESUMEN

OBJECTIVE: Initial treatment options for Graves' disease include antithyroid drugs, radioactive iodine (RAI), and surgery. Because of similar effects of three modalities, initial treatment preferences differ by country to country. In Korea, iodine-replete area, RAI was used as a second-line option. For these reasons, the RAI success rate in Korea might differ from other countries. METHODS: A total of 247 patients were enrolled. The primary outcome was cumulative success rate in the first year, and the secondary outcome was factors that affected the success. Delayed response, which included patients who attained successful RAI during the follow-up, after the first year without further RAI, and factors that affected the delayed response were reviewed. RESULTS: The cumulative success rate in the first year was 62.8%. Higher RAI activity [odds ratio (OR) 2.56, P = 0.02], longer disease duration (OR 0.43, P = 0.01), larger goiter (OR 0.31, P = 0.01), and higher post-RAI fT4 (fT4 between upper normal limit (UNL) to 1.5 × UNL; OR 0.24; P < 0.01, 1.5 × UNL<; OR 0.08; P < 0.01) were associated with RAI success. Twenty-seven patients showed delayed response, and goiter size (P < 0.05), pre-RAI TSH receptor Ab (TRAb) level (P < 0.01) and post-RAI fT4 (P < 0.01) were associated. CONCLUSION: The success rate of the first RAI in Korea was lower than that in other countries. Delayed response was observed in patients with smaller goiter, low pre-RAI TRAb, and low post-RAI fT4. In these patients, clinical follow-up with monitoring could be an option, and decision of optimal timing of first RAI is crucial.


Asunto(s)
Enfermedad de Graves/radioterapia , Radioisótopos de Yodo/uso terapéutico , Yodo , Adulto , Dieta , Femenino , Estudios de Seguimiento , Bocio/radioterapia , Enfermedad de Graves/cirugía , Humanos , Masculino , Persona de Mediana Edad , Receptores de Tirotropina/análisis , Receptores de Tirotropina/metabolismo , República de Corea , Estudios Retrospectivos , Tiroidectomía , Tiroxina/sangre , Resultado del Tratamiento
7.
Cell Biol Int ; 43(5): 486-494, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30761678

RESUMEN

Hypothyroidism has been linked to infertility, but the mechanisms underlying infertility-related hypothyroidism have yet to be fully elucidated. Therefore, in this study, effects of hypothyroidism on expression of the proteins related to thyroid hormone function in the uterus, which were thought to play a role implantation, including thyroid hormone receptor (TR), thyroid stimulating hormone receptor (TSHR), retinoic acid receptor (RAR) and extracellular kinase (ERK) were identified. Pregnant female rats were rendered hypothyroid by giving methimazole (MMI), orally. Following hypothyroid induction, rats were grouped into control (non-treated) and received subcutaneous thyroxine at 20, 40, and 80 µg/kg/day for five consecutive days. At Day 6, which is the day of implantation (GD 6), rats were sacrificed and the number of embryo implantation site in the uterus was calculated. Then, uterine horns were harvested and expression of the above proteins and their mRNAs were identified by Western blotting and real-time PCR, respectively. In non-treated hypothyroid pregnant rats, the number of embryo implantation sites decreased as compared to euthyroid and hypothyroid rats receiving thyroxine treatment. Similarly, expression of TRα-1, TRß-1, TSHR, ERK1/2 and RAR proteins and mRNA in the uterus of non-treated hypothyroid rats also decreased (P < 0.05 when compared to euthyroid and thyroxine-treated hypothyroid rats). In conclusion, downregulated expression of the thyroid hormone related proteins in the uterus at the day of implantation might result in infertility as reported in hypothyroid condition.


Asunto(s)
Hipotiroidismo/fisiopatología , Glándula Tiroides/metabolismo , Hormonas Tiroideas/metabolismo , Animales , Regulación hacia Abajo/efectos de los fármacos , Implantación del Embrión , Femenino , Regulación del Desarrollo de la Expresión Génica/genética , Hipotiroidismo/complicaciones , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Metimazol/farmacología , Embarazo , Ratas , Ratas Sprague-Dawley , Receptores de Ácido Retinoico/análisis , Receptores de Ácido Retinoico/metabolismo , Receptores de Hormona Tiroidea/análisis , Receptores de Hormona Tiroidea/metabolismo , Receptores de Tirotropina/análisis , Receptores de Tirotropina/metabolismo , Glándula Tiroides/fisiología , Hormonas Tiroideas/genética , Hormonas Tiroideas/fisiología , Tiroxina/farmacología , Útero/metabolismo , Útero/fisiología
8.
Cell Mol Life Sci ; 75(12): 2227-2239, 2018 06.
Artículo en Inglés | MEDLINE | ID: mdl-29290039

RESUMEN

G-protein-coupled receptors (GPCRs) can constitute complexes with non-GPCR integral membrane proteins, while such interaction has not been demonstrated at a single molecule level so far. We here investigated the potential interaction between the thyrotropin receptor (TSHR) and the monocarboxylate transporter 8 (MCT8), a member of the major facilitator superfamily (MFS), using fluorescence cross-correlation spectroscopy (FCCS). Both the proteins are expressed endogenously on the basolateral plasma membrane of the thyrocytes and are involved in stimulation of thyroid hormone production and release. Indeed, we demonstrate strong interaction between both the proteins which causes a suppressed activation of Gq/11 by TSH-stimulated TSHR. Thus, we provide not only evidence for a novel interaction between the TSHR and MCT8, but could also prove this interaction on a single molecule level. Moreover, this interaction forces biased signaling at the TSHR. These results are of general interest for both the GPCR and the MFS research fields.


Asunto(s)
Transportadores de Ácidos Monocarboxílicos/metabolismo , Mapas de Interacción de Proteínas , Receptores de Tirotropina/metabolismo , Animales , Células COS , Chlorocebus aethiops , Expresión Génica , Células HEK293 , Humanos , Transportadores de Ácidos Monocarboxílicos/análisis , Transportadores de Ácidos Monocarboxílicos/genética , Multimerización de Proteína , Receptores de Tirotropina/análisis , Receptores de Tirotropina/genética , Transducción de Señal , Simportadores , Glándula Tiroides/metabolismo , Glándula Tiroides/patología
9.
Mediators Inflamm ; 2017: 8102170, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29375200

RESUMEN

Prevalence of thyroid dysfunction and its impact on cognition in older people has been demonstrated, but many points remain unclarified. In order to study the effect of aging on the thyroid gland, we compared the thyroid gland of very old mice with that of younger ones. We have first investigated the changes of thyroid microstructure and the possibility that molecules involved in thyroid function might be associated with structural changes. Results from this study indicate changes in the height of the thyrocytes and in the amplitude of interfollicular spaces, anomalous expression/localization of thyrotropin, thyrotropin receptor, and thyroglobulin aging. Thyrotropin and thyrotropin receptor are upregulated and are distributed inside the colloid while thyroglobulin fills the interfollicular spaces. In an approach aimed at defining the behavior of molecules that change in different physiopathological conditions of thyroid, such as galectin-3 and sphingomyelinase, we then wondered what was their behavior in the thyroid gland in aging. Importantly, in comparison with the thyroid of young animals, we have found a higher expression of galectin-3 and a delocalization of neutral sphingomyelinase in the thyroid of old animals. A possible relationship between galectin-3, neutral sphingomyelinase, and aging has been discussed.


Asunto(s)
Envejecimiento/patología , Galectina 3/fisiología , Esfingomielina Fosfodiesterasa/fisiología , Glándula Tiroides/patología , Animales , Galectina 3/análisis , Masculino , Ratones , Receptores de Tirotropina/análisis , Esfingomielina Fosfodiesterasa/análisis , Tirotropina/análisis
10.
Endocrinol. nutr. (Ed. impr.) ; 60(10): 590-598, dic. 2013. ilus, tab
Artículo en Inglés | IBECS | ID: ibc-118144

RESUMEN

Tanto el crecimiento como la función de la glándula tiroides son regulados por la tirotropina (TSH), la cual ejerce su función a través de su receptor (TSHR). El TSHR es el antígeno clave en varias alteraciones tiroideas, entre las que se incluyen el hipertiroidismo y el hipotiroidismo, o en algunos tumores. Actualmente, se disponen de diversas estrategias terapéuticas para muchos de estos trastornos, como son los fármacos antitiroideos o la administración de radioyodo. Desgraciadamente, estas terapias no están exentas de efectos secundarios. Además, el tratamiento de las complicaciones derivadas de la enfermedad de Graves, como la oftalmopatía tiroidea, resulta muchas veces difícil e insatisfactorio. Los recientes avances en investigación básica, tanto en modelos in vitro como in vivo, sugieren que los análogos de la TSH podrían emplearse en el diagnóstico y en el tratamiento en algunas de las enfermedades tiroideas. La llegada de los métodos de cribado de alto rendimiento ha proporcionado un grupo de análogos de la TSH, también llamados pequeñas-moléculas, que son fármacos con características potencialmente prometedoras. Estas pequeñas-moléculas son sustancias con bajo peso molecular que pueden poseer actividad agonista, antagonista y, en algunos casos, agonista inversa sobre el TSHR. En esta revisión nos centraremos en los avances actuales en el desarrollo de los análogos de la TSH y su posible aplicación clínica. Los rápidos avances en este campo podrían propiciar que en los próximos años se desarrollen ensayos clínicos con pequeñas-moléculas relacionadas con el TSHR para pacientes con enfermedad de Graves, cáncer de tiroides y osteoporosis de origen tiroideo (AU)


The thyroid-stimulating hormone (TSH) receptor (TSHR) is a major regulator of thyroid function and growth, and is the key antigen in several pathological conditions including hyperthyroidism, hypothyroidism, and thyroid tumors. Various effective treatment strategies are currently available for many of these clinical conditions such as antithyroid drugs or radioiodine therapy, but they are not devoid of side effects. In addition, treatment of complications of Graves’ disease such as Graves’ ophthalmopathy is often difficult and unsatisfactory using current methods. Recent advances in basic research on both in vitro and in vivo models have suggested that TSH analogs could be used for diagnosis and treatment of some of the thyroid diseases. The advent of high-throughput screening methods has resulted in a group of TSH analogs called small molecules, which have the potential to be developed as promising drugs. Small molecules are low molecular weight compounds with agonist, antagonist and, in some cases, inverse agonist activity on TSHR. This short review will focus on current advances in development of TSH analogs and their potential clinical applications. Rapid advances in this field may lead to the conduct of clinical trials of small molecules related to TSHR for the management of Graves’ disease, thyroid cancer, and thyroid-related osteoporosis in the coming years (AU)


Asunto(s)
Humanos , Enfermedades de la Tiroides/fisiopatología , Receptores de Tirotropina/análisis , Pruebas de Función de la Tiroides , Hormonas Tiroideas/análisis , Neoplasias de la Tiroides/patología , Enfermedad de Graves/fisiopatología
11.
Endocrinol Nutr ; 60(10): 590-8, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23538281

RESUMEN

The thyroid-stimulating hormone (TSH) receptor (TSHR) is a major regulator of thyroid function and growth, and is the key antigen in several pathological conditions including hyperthyroidism, hypothyroidism, and thyroid tumors. Various effective treatment strategies are currently available for many of these clinical conditions such as antithyroid drugs or radioiodine therapy, but they are not devoid of side effects. In addition, treatment of complications of Graves' disease such as Graves' ophthalmopathy is often difficult and unsatisfactory using current methods. Recent advances in basic research on both in vitro and in vivo models have suggested that TSH analogs could be used for diagnosis and treatment of some of the thyroid diseases. The advent of high-throughput screening methods has resulted in a group of TSH analogs called small molecules, which have the potential to be developed as promising drugs. Small molecules are low molecular weight compounds with agonist, antagonist and, in some cases, inverse agonist activity on TSHR. This short review will focus on current advances in development of TSH analogs and their potential clinical applications. Rapid advances in this field may lead to the conduct of clinical trials of small molecules related to TSHR for the management of Graves' disease, thyroid cancer, and thyroid-related osteoporosis in the coming years.


Asunto(s)
Receptores de Tirotropina/análisis , Enfermedades de la Tiroides/tratamiento farmacológico , Enfermedad de Graves/tratamiento farmacológico , Humanos , Neoplasias de la Tiroides/tratamiento farmacológico
12.
Methods Enzymol ; 521: 367-83, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23351750

RESUMEN

As for other GPCRs, the oligomerization of glycoprotein hormone receptors (GPHRs) appears as critical event for receptor function. By means of modern techniques based on the BRET or FRET principle, GPHR oligomerization has been reported to explain several physiological and pathological conditions. In particular, the presence of oligomers was demonstrated not only in in vitro heterologous systems but also in in vivo tissues, and GPHR homodimerization appears associated with strong negative cooperativity, thus suggesting that one hormone molecule may be sufficient for receptor dimer stimulation. In addition, oligomerization has been reported to occur early during the posttranslational maturation process and to be involved in the dominant negative effect exerted by loss-of-function TSH receptor (TSHR) mutants, that are prevalently retained inside the cell, on the surface expression of wild-type receptors. This molecular mechanism thus explains the dominant inheritance of certain forms of TSH resistance. Here, we provide the description of the methods used in the original BRET, FRET, and HTRF-RET experiments.


Asunto(s)
Transferencia de Energía por Resonancia de Bioluminiscencia/métodos , Transferencia Resonante de Energía de Fluorescencia/métodos , Receptores de HFE/metabolismo , Receptores de HL/metabolismo , Receptores de Tirotropina/metabolismo , Animales , Transferencia de Energía , Humanos , Multimerización de Proteína , Receptores de HFE/análisis , Receptores de HFE/genética , Receptores de HL/análisis , Receptores de HL/genética , Receptores de Tirotropina/análisis , Receptores de Tirotropina/genética , Transfección/métodos
13.
Rev. lab. clín ; 5(4): 188-194, oct.-dic. 2012.
Artículo en Español | IBECS | ID: ibc-107854

RESUMEN

Introducción. Los programas para cribado neonatal utilizan muestras de sangre impregnada en papel, en ellas se determinan los marcadores de las patologías incluidas. La presencia de anticoagulantes en las muestras puede producir interferencias en los métodos de medida y se recomienda su no utilización. No es posible reconocer las muestras recogidas con anticoagulante. Material y métodos. Se desarrolló y optimizó un procedimiento por espectrometría de masas en tándem con electrospray (ESI-MS/MS) para la determinación de EDTA (ácido etilendiaminotetraacético) en las muestras de sangre en papel y se valoró su inclusión en el perfil de aminoácidos y acilcarnitinas utilizado para la detección precoz neonatal de enfermedades metabólicas. Se estudió su influencia sobre las medidas de tirotropina (TSH), realizadas para el cribado neonatal de hipotiroidismo congénito. Resultados. Se optimizaron los parámetros que permiten la medida de EDTA en el eluato de sangre. Se ha determinado TSH en sangre en papel, suero y plasma de un grupo de 110 muestras y EDTA en otro grupo de 2.300 muestras provenientes del programa de cribado neonatal detectando su presencia en un 0,74% de las mismas. Conclusiones. El método desarrollado es válido para la determinación de este anticoagulante y se puede incluir en el perfil de aminoácidos y acilcarnitinas por MS/MS para detectar aquellas muestras que se extrajeron inadecuadamente. Se ha confirmado la influencia negativa del EDTA en la determinación de TSH mediante un fluoroinmunoensayo (AutoDELFIA(R)). Esto podría provocar un falso negativo en el cribado neonatal de hipotiroidismo congénito (AU)


Introduction. Newborn screening programs use blood impregnated paper to analyze disease markers. The presence of EDTA in samples may interfere in the analytical methods used to measure these markers. For this reason, it is recommended not use anticoagulants in these samples. Moreover, it is not possible to recognize samples that have been collected into EDTA. Material and Methods. We developed and optimized an electrospray tandem mass spectrometry (ES-MS/MS) method to determine EDTA (ethylenediaminetetraacetic acid) in dried blood spots (DBS) on paper. We also included the method in the amino acids and acylcarnitines profile used for metabolic diseases neonatal screening. We also studied the EDTA influence on thyrotropin (TSH) neonatal screening analysis. Results. Optimized parameters for EDTA analysis in the blood eluate were found. TSH analysis was performed on DBS, serum and plasma samples from 110 patients. EDTA analysis on 2000 neonatal screening samples detected 0.74% of cases with EDTA contamination. Conclusions. The negative influence of EDTA in the determination of TSH by fluoroimmunoassay (AutoDELFIA(R)) has been confirmed. This could cause a false negative in neonatal screening for congenital hypothyroidism. The developed method is valid for the determination of this blood anticoagulant and can be included in the profile of amino acids and acylcarnitines by MS / MS to detect those samples that were taken improperly (AU)


Asunto(s)
Humanos , Masculino , Femenino , Espectrometría de Masas en Tándem/métodos , Espectrometría de Masas en Tándem/normas , Espectrometría de Masas en Tándem , Diagnóstico Prenatal/instrumentación , Diagnóstico Prenatal/métodos , Receptores de Tirotropina/análisis , Tirotropina , Enfermedades Metabólicas/diagnóstico , Diagnóstico Precoz , Hipotiroidismo Congénito/diagnóstico , Espectrometría de Masas en Tándem/clasificación , Espectrometría de Masas en Tándem/instrumentación , Espectrometría de Masas en Tándem/tendencias , Hipotiroidismo Congénito , Hipotiroidismo/diagnóstico , Mediciones Luminiscentes/métodos
14.
Menopause ; 19(11): 1253-9, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22713859

RESUMEN

OBJECTIVE: Thyroid gland dysfunction is associated with menstrual cycle disturbances, infertility, and increased risk of miscarriage, but the mechanisms are poorly understood. However, little is known about the regulation of these receptors in the uterus. The aim of this study was to determine the effects of long-term treatment with steroid hormones on the expression, distribution, and regulation of the receptors for thyrotropin-releasing hormone (TRHR) and thyroid-stimulating hormone (TSHR), thyroid hormone receptor α1/α2 (THRα1/α2), and THRß1 in the uterus of surgically menopausal monkeys. METHODS: Eighty-eight cynomolgus macaques were ovariectomized and treated orally with conjugated equine estrogens (CEE; n = 20), a combination of CEE and medroxyprogesterone acetate (MPA; n = 20), or tibolone (n = 28) for 2 years. The control group (OvxC; n = 20) received no treatment. Immunohistochemistry was used to evaluate the protein expression and distribution of the receptors in luminal epithelium, glands, stroma, and myometrium of the uterus. RESULTS: Immunostaining of TRHR, TSHR, and THRs was detected in all uterine compartments. Epithelial immunostaining of TRHR was down-regulated in the CEE + MPA group, whereas in stroma, both TRHR and TSHR were increased by CEE + MPA treatment as compared with OvxC. TRHR immunoreactivity was up-regulated, but THRα and THRß were down-regulated, in the myometrium of the CEE and CEE + MPA groups. The thyroid-stimulating hormone level was higher in the CEE and tibolone groups as compared with OvxC, but the level of free thyroxin did not differ between groups. CONCLUSIONS: All receptors involved in thyroid hormone function are expressed in monkey uterus, and they are all regulated by long-term steroid hormone treatment. These findings suggest that there is a possibility of direct actions of thyroid hormones, thyroid-stimulating hormone and thyrotropin-releasing hormone on uterine function.


Asunto(s)
Hormonas Esteroides Gonadales/farmacología , Macaca fascicularis , Receptores de Hormona Tiroidea/efectos de los fármacos , Receptores de Hormona Liberadora de Tirotropina/efectos de los fármacos , Receptores de Tirotropina/efectos de los fármacos , Útero/química , Animales , Estrógenos Conjugados (USP)/administración & dosificación , Femenino , Inmunohistoquímica/veterinaria , Acetato de Medroxiprogesterona/administración & dosificación , Norpregnenos/administración & dosificación , Receptores de Hormona Tiroidea/análisis , Receptores de Tirotropina/análisis , Receptores de Hormona Liberadora de Tirotropina/análisis , Receptores alfa de Hormona Tiroidea/análisis , Receptores alfa de Hormona Tiroidea/efectos de los fármacos , Receptores beta de Hormona Tiroidea/análisis , Receptores beta de Hormona Tiroidea/efectos de los fármacos , Útero/fisiología
15.
J Clin Endocrinol Metab ; 97(7): E1106-15, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22496495

RESUMEN

CONTEXT: Stimulating thyrotropin receptor (TSHr) autoantibodies (TSAb) are the cause of hyperthyroidism in Graves' disease. In a patient's serum, TSAb can coexist with antagonist TSHr autoantibodies that block TSAb stimulatory activity (TSBAb); both can vary in amount and time. OBJECTIVE: The objective of the study was to create a functional assay that detects only TSAb, thus having an increased accuracy for diagnosing Graves' disease. DESIGN: A TSHr chimera (Mc4) that retains an agonist-sensitive TSAb epitope but replaces a TSBAb epitope was stably transfected in cells to establish the Mc4 assay. SETTING: The study was conducted at the Chieti University (Outpatient Endocrine Clinic) and the University of Pisa (the Department of Endocrinology). PATIENTS: The assay was validated using sera from 170 individuals with Graves' disease, Hashimoto's thyroiditis, and nonautoimmune hyperthyroidism and normal subjects from Chieti University. A second blinded study evaluated sera from 175 patients with autoimmune thyroid disease (mainly Graves' disease) from the University of Pisa. INTERVENTIONS: Interventions included the assessment of patients' sera using human wild-type TSHr (WT-TSHr), Mc4 chimera, and binding (TRAb) assays. MAIN OUTCOME MEASURES: The Mc4 assay has the best accuracy for diagnosing Graves' disease. RESULTS: The Mc4 assay has a better diagnostic accuracy than WT-TSHr and second-generation TRAb assays. Indeed, the sensitivity of the WT-TSHr, TRAb, and Mc4 assays was 97.3, 86.5, and 100%, respectively, whereas the specificity was 93.1, 97, and 98.5%, respectively. CONCLUSION: The Mc4 assay is a functional assay with improved sensitivity and specificity for the detection of TSAb and is clinically useful in diagnosing Graves' disease.


Asunto(s)
Enfermedad de Graves/diagnóstico , Inmunoglobulinas Estimulantes de la Tiroides/análisis , Receptores de HL/análisis , Receptores de Tirotropina/análisis , Proteínas Recombinantes de Fusión , Adulto , Anciano , Animales , Autoanticuerpos/análisis , Autoanticuerpos/sangre , Células CHO , Estudios de Casos y Controles , Células Cultivadas , Cricetinae , Femenino , Enfermedad de Graves/sangre , Enfermedad de Graves/inmunología , Células HEK293 , Humanos , Inmunoglobulinas Estimulantes de la Tiroides/sangre , Masculino , Persona de Mediana Edad , Visón , Receptores de HL/química , Receptores de HL/fisiología , Receptores de Tirotropina/química , Receptores de Tirotropina/fisiología , Proteínas Recombinantes de Fusión/análisis , Pruebas de Función de la Tiroides/métodos
16.
J Clin Endocrinol Metab ; 97(7): E1080-7, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22492869

RESUMEN

CONTEXT: A functional thyroid-stimulating autoantibodies (TSAb) assay using a thyroid-stimulating hormone receptor chimera (Mc4) appears to be clinically more useful than the commonly used assay, a binding assay that measures all the antibodies binding to the thyroid-stimulating hormone receptor without functional discrimination, in diagnosing patient with Graves' disease (GD). OBJECTIVE: The objective of the study was to investigate whether an Mc4 assay can predict relapse/remission of hyperthyroidism after antithyroid drug (ATD) treatment in patients with GD. DESIGN: An Mc4 assay was used to prospectively track TSAb activity in GD patients treated with ATD over a 5-yr period. SETTING AND PATIENTS: GD patients from the Chieti University participated in this study. INTERVENTIONS: Interventions included the assessment of patients' sera using the Mc4 assay, the Mc4-derivative assay (Thyretain), and a human monoclonal thyroid-stimulating hormone receptor antibody, M22 assay. MAIN OUTCOME MEASURES: The Mc4 assay, a sensitive index of remission and recurrence, was used in this study. RESULTS: The TSAb levels significantly decreased only in the remitting group as evidenced by Mc4 assay values at the end of ATD (0.96 ± 1.47, 10.9 ± 26.6. and 24.7 ± 37.5 arbitrary units for the remitting, relapsing, and unsuspended therapy groups, respectively). Additional prognostic help was obtained by thyroid volume measurements at the end of treatment. Although not statistically significant, the Mc4 assay has a trend toward improved positive predictive value (95.4 vs. 84.2 or 87.5%), specificity (96.4 vs. 86.4 and 90.9%), and accuracy (87.3 vs. 83.3 and 80.9%) comparing the Mc4, Thyretain, and M22 assays, respectively. Thyretain has a trend toward improved negative predictive value (82.6 vs. 81.8 and 76.9%) and sensitivity (80 vs. 77.8 and 70%) comparing Thyretain, Mc4, and M22 assays, respectively. CONCLUSION: The Mc4 assay is a clinically useful index of remission and relapse in patients with GD. Larger studies are required to confirm these findings.


Asunto(s)
Enfermedad de Graves/diagnóstico , Inmunoglobulinas Estimulantes de la Tiroides/análisis , Receptores de HL/análisis , Receptores de Tirotropina/análisis , Proteínas Recombinantes de Fusión , Adulto , Animales , Antitiroideos/uso terapéutico , Autoanticuerpos/análisis , Autoanticuerpos/sangre , Células CHO , Ensayos Clínicos como Asunto/métodos , Cricetinae , Cricetulus , Femenino , Estudios de Seguimiento , Enfermedad de Graves/sangre , Enfermedad de Graves/tratamiento farmacológico , Enfermedad de Graves/inmunología , Células HEK293 , Humanos , Inmunoglobulinas Estimulantes de la Tiroides/sangre , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Pronóstico , Receptores de HL/química , Receptores de HL/fisiología , Receptores de Tirotropina/química , Receptores de Tirotropina/fisiología , Proteínas Recombinantes de Fusión/farmacología , Recurrencia , Inducción de Remisión , Pruebas de Función de la Tiroides/métodos , Adulto Joven
17.
Rev. lab. clín ; 4(2): 84-89, abr.-jun. 2011.
Artículo en Español | IBECS | ID: ibc-88076

RESUMEN

La medida en suero de la concentración de tirotropina y tiroxina es la base para la evaluación bioquímica de la función tiroidea. Con frecuencia, el intervalo de referencia de la tirotropina sirve como cribado inicial para valorar la necesidad de añadir la medida de tiroxina. Este trabajo se ha realizado con el objetivo de mejorar la sensibilidad diagnóstica del cribado. Se seleccionaron todos los resultados de tirotropina y tiroxina solicitados de manera simultánea a pacientes de consultas externas: para la primera parte del estudio se usaron los del año 2008 (n=10.900) y para la segunda parte, los de pacientes del año 2009 sin seguimiento en el año previo (n=5.367). Se realizaron dos curvas ROC para delimitar el intervalo de decisión del algoritmo con una sensibilidad del 90% y se contabilizó el número de resultados falsos negativos obtenidos. Los intervalos de tirotropina obtenidos en el primer y segundo estudio fueron (2,11-3,50) mint.u./L y (2,04-3,41) mint.u/L respectivamente. En ambos estudios la sensibilidad aumentó aproximadamente de un 70% de media con el intervalo de referencia a un 90% con el intervalo del algoritmo. El número de falsos negativos se redujo de 75 a 30 en el primer caso, y de 37 a 13 en el segundo. La aplicación de un intervalo de tirotropina calculado para la evaluación de la función tiroidea, en pacientes ambulatorios con o sin seguimiento previo, supone un aumento en la sensibilidad diagnóstica, respecto al empleo del intervalo de referencia de tirotropina (AU)


The measurement of thyrotropin and thyroxine concentrations in serum is the basis of the biochemical evaluation of thyroid function. The reference interval of thyrotropin is frequently used as an initial screening to assess the need for thyroxine measurement. This study was carried out to obtain a different and more adjusted interval of thyrotropin, in order to improve the diagnostic sensitivity. All of the results of thyrotropin and thyroxine requested at the same time on outpatients were selected: for the first part of the study, those from year 2008 (n=10,900), and for the second part, those from 2009 with no follow-up in the previous year (n=5,367). Two ROC curves were used to define the algorithm decision interval with a sensitivity of 90% and the number of false negative results was calculated. The thyrotropin intervals obtained in the first and second studies were (2.11-3.50) mIU/L and (2.04-3.41) mIU/L, respectively. In both studies, the sensitivity increased approximately from an average of 70% to 90% of the confidence interval using the algorithm interval. The number of false negatives was reduced from 75 to 30 in the first case, and from 37 to 13 in the second case. The application of a calculated thyrotropin interval to assess thyroid function in outpatients with or without prior monitoring, leads to an increase of the diagnostic sensitivity with regard to the use of the thyrotropin reference interval (AU)


Asunto(s)
Humanos , Masculino , Femenino , Sensibilidad y Especificidad , Pruebas de Función de la Tiroides/métodos , Pruebas de Función de la Tiroides , Tamizaje Masivo/métodos , Pruebas de Función de la Tiroides/tendencias , Receptores de Tirotropina/análisis , Tirotropina/análisis , Tiroxina/análisis , Tiroxina , Curva ROC
18.
J Endocrinol Invest ; 33(6): 414-21, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20631493

RESUMEN

The most important of the extra-thyroidal manifestations of Graves' disease, Graves' orbitopathy (GO), remains a vexing clinical problem. Treatment of severe active disease has been limited to steroids or radiotherapy. In the relatively rare case where vision is threatened, emergent decompression surgery can be performed. The proptosis, motility, or cosmetic concerns associated with stable GO are commonly remedied with surgical intervention. Substantial obstacles have prevented the development of specific medical therapies for GO, in large part resulting from poor understanding of disease pathogenesis and the absence of preclinical animal models. Fundamental aspects of GO's etiology have been uncovered from studies based in cell culture, extensive analysis of blood constituents, and detailed examination of orbital contents collected at the time of surgical intervention. Many of the published reports resulting from these studies are descriptive and all have failed to yield unifying concepts that integrate the anatomically divergent manifestations of Graves' disease. This brief review covers recent findings of several research groups. While major breakthroughs continue to occur in closely related autoimmune diseases, progress in identifying the pathogenic mechanisms relevant to GO has been limited. As emerging insights into human autoimmunity becomes applied to the study of Graves' disease, we anticipate that improved therapeutic strategies will find their way to our patients with GO.


Asunto(s)
Oftalmopatía de Graves/etiología , Antígenos CD34/análisis , Autoinmunidad , Células de la Médula Ósea/citología , Fibroblastos/fisiología , Enfermedad de Graves/radioterapia , Oftalmopatía de Graves/inmunología , Oftalmopatía de Graves/terapia , Humanos , Radioisótopos de Yodo/efectos adversos , Proteínas de Microfilamentos/análisis , Fenotipo , Receptor IGF Tipo 1/biosíntesis , Receptores de Tirotropina/análisis
20.
An. pediatr. (2003, Ed. impr.) ; 72(2): 121-127, feb. 2010. tab, ilus
Artículo en Español | IBECS | ID: ibc-77179

RESUMEN

Introducción: Se midió hipertirotropinemia neonatal en 3 provincias del sur de España y se analizó la repercusión de una posible deficiencia de yodo en un programa de cribado de hipotiroidismo congénito (CH, congenital hypothyroidism). Material y métodos: El estudio comprende 113.108 recién nacidos que se dividieron en 2 grupos según el momento en que se extrajo la muestra para el cribado. En 78.646 se recogió después de las 48h de vida y en 34.462 se obtuvo en el momento del nacimiento del cordón umbilical (muestras precoces). Los recién nacidos procedían de las provincias de Sevilla, Huelva y Córdoba. La tirotropina (TSH) se midió por fluorimetría a tiempo discriminado. Resultados: El porcentaje de hipertirotropinemia neonatal fue superior en Huelva (5,2%) que en Sevilla (1%) (p<0,001), hecho constatado igualmente en el grupo de muestras precoces (Huelva: 5,3%; Sevilla: 1,9%, y Córdoba: 1,7%: p<0,001). En este último grupo, el 0,3 y el 0,2% de los recién nacidos de Sevilla y Córdoba, respectivamente, presentaron TSH >20mUI/l y 10 recién nacidos tuvieron que localizarse por cada recién nacido con CH. En Huelva hubo que llamar a 17 recién nacidos por caso detectado. Conclusiones: La distribución heterogénea de las concentraciones de TSH en los recién nacidos de las 3 áreas geográficas parece indicar una ingesta de yodo irregular y deficiente. La extracción de muestras precoces más una posible deficiencia de yodo incrementa el número de falsos positivos en el programa de cribado neonatal de CH (AU)


Background: Neonatal hyperthyrotropinemia by measurements of thyrotropin (TSH) concentrations has been assessed in three different areas of Spain. The repercussions of a possible iodine deficiency in a congenital hypothyroidism screening program have also been analysed. Material and Methods: The study comprised 113,108 newborns, which were divided into two groups according to the time of blood sampling. In 78,646 newborns heel blood samples were obtained after 48h whereas in 34,462 newborns, samples were obtained at birth from the umbilical cord (early samples). Newborns came from three areas of the south of Spain, Seville, Huelva and Cordoba. TSH concentrations were measured by time-resolved fluoroimmunoassay. Results: The percentage of hyperthyrotropinemia was greater in Huelva (5.2%) than Seville (1.0%) (p<0.001), similar to that observed in early samples, which was higher in Huelva (5.3%) than in Seville (1.9%) and Cordoba (1.7%) (p<0.001). In the early samples group, 0.3% and 0.2% of the newborns from Seville and Cordoba respectively, had TSH >20mIU/L and 10 infants should have been recalled for a new sample for each case detected. While in Huelva 17 infants (0.9%) were recalled per case detected. Conclusions: The heterogeneous distribution of TSH concentrations in newborns from several geographical areas appears to indicate an irregular and deficient iodine intake. Using early samples and a possible iodine deficiency, increase false positive results in a Neonatal Screening Program of congenital hypothyroidism (AU)


Asunto(s)
Humanos , Masculino , Femenino , Niño , Deficiencia de Yodo/complicaciones , Deficiencia de Yodo/diagnóstico , Deficiencia de Yodo/terapia , Hipotiroidismo/complicaciones , Hipotiroidismo/genética , Fluorometría/métodos , Fluorometría , Receptores de Tirotropina/análisis , Tirotropina/análisis , Tirotropina , Tamizaje Masivo/métodos , Salud Pública/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA